The voluntary nationwide recall stems from elevated levels of impurity detected during recent routine quality testing. No adverse events have been reported. However, elevated impurities have the potential to result in neuromuscular blockage in patients with renal failure.
Affected lots were distributed between January and May 2012.
More Articles on Anesthesia:
Anesthesia Business Consultants, iMDsoft Develop Cloud-Based Anesthesia EMR
Dr. Peter Sybert Elected President of California Society of Anesthesiologists
Study: Mount Sinai Anesthesiology Retraining Program Sees 70% Return to Practice
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
